Palivizumab prophylaxis: How to compare pre- and post-prophylaxis eras? [4]

Pediatric Pulmonology

Volumn 42, Issue 7, 2007, Pages 660-

  Korppi, Matti ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

CHILD HOSPITALIZATION; DRUG EFFICACY; DRUG INDICATION; HUMAN; INFECTION PREVENTION; LETTER; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 34347395356     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20613     Document Type: Letter

References (6)

1. Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon J-P. Palivizumab efficacy in preterm infants with gestational age ≤30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol 2007;42:189-192.
2. Naver L, Eriksson M, Ewald U, Linde A, Lindroth M, Schollin J. Appropriate prophylaxis with restrictive palivizumab regimen in pre-term children in Sweden. Acta Paediatr 2004;93:1470-1473.
3. Heikkinen T, Valkonen H, Lehtonen L, Vainionpaa R, Ruuskanen O. High risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal neonatal Ed 2005;90:F64-F68.
4. The Impact-RSV study group. Palivizumab, a homogenized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-537.
5. Waris M. Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B. J Infect Dis 1991;163:464-469.
6. Korppi M, Hiltunen J. Pertussis is common in nonvaccinated infants hospitalized for respiratory syncytial virus infection. Pediatr Infect Dis J 2007;26:316-318.